Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 8, 2026 · Investor press release · Financial statements
Vor Biopharma Inc.
8
Investor press release
Jun 8, 2026
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
Vor Biopharma Inc. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England Journal of Medicine IgAN marks the fourth indicatio…
The filing reports Items 7.01, 9.01. None of these codes are typically workforce-tagged, but analysts still review them for indirect labor-market signals.
Vor Biopharma Inc. filed this 8-K with the SEC. cutoffs links it to the employer's layoff history, visa filings, and other labor-market signals.
